JP2018527014A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527014A5
JP2018527014A5 JP2018515108A JP2018515108A JP2018527014A5 JP 2018527014 A5 JP2018527014 A5 JP 2018527014A5 JP 2018515108 A JP2018515108 A JP 2018515108A JP 2018515108 A JP2018515108 A JP 2018515108A JP 2018527014 A5 JP2018527014 A5 JP 2018527014A5
Authority
JP
Japan
Prior art keywords
acid sequence
cell
hiv
nucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515108A
Other languages
English (en)
Japanese (ja)
Other versions
JP6991131B2 (ja
JP2018527014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053097 external-priority patent/WO2017053556A1/en
Publication of JP2018527014A publication Critical patent/JP2018527014A/ja
Publication of JP2018527014A5 publication Critical patent/JP2018527014A5/ja
Application granted granted Critical
Publication of JP6991131B2 publication Critical patent/JP6991131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515108A 2015-09-22 2016-09-22 Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法 Active JP6991131B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562222132P 2015-09-22 2015-09-22
US62/222,132 2015-09-22
US201562253790P 2015-11-11 2015-11-11
US62/253,790 2015-11-11
PCT/US2016/053097 WO2017053556A1 (en) 2015-09-22 2016-09-22 Method of redirecting t cells to treat hiv infection

Publications (3)

Publication Number Publication Date
JP2018527014A JP2018527014A (ja) 2018-09-20
JP2018527014A5 true JP2018527014A5 (enExample) 2019-10-31
JP6991131B2 JP6991131B2 (ja) 2022-02-03

Family

ID=58387210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515108A Active JP6991131B2 (ja) 2015-09-22 2016-09-22 Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法

Country Status (15)

Country Link
US (3) US10738099B2 (enExample)
EP (1) EP3353197A4 (enExample)
JP (1) JP6991131B2 (enExample)
KR (1) KR20180050413A (enExample)
CN (1) CN108779161A (enExample)
AU (1) AU2016326500A1 (enExample)
BR (1) BR112018005741A2 (enExample)
CA (1) CA2999496A1 (enExample)
CL (1) CL2018000750A1 (enExample)
EA (1) EA201890782A1 (enExample)
IL (1) IL258191A (enExample)
MA (1) MA42951A (enExample)
MX (1) MX2018003463A (enExample)
PH (1) PH12018500609A1 (enExample)
WO (1) WO2017053556A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
MX2018003463A (es) * 2015-09-22 2018-09-06 Univ Pennsylvania Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
LT3443006T (lt) 2016-04-13 2023-10-25 Sanofi Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2018208606A1 (en) * 2017-05-08 2018-11-15 The Regents Of The University Of California Protective chimeric antigen receptor stem cell gene therapy for viral infection
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
JP7164598B2 (ja) * 2017-05-17 2022-11-01 サンダー・バイオテック・インコーポレイテッド トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
US12496338B2 (en) 2017-10-23 2025-12-16 City Of Hope CAR for treatment of HIV infection
CN108059675B (zh) * 2017-12-12 2021-09-10 武汉波睿达生物科技有限公司 重组pg9-car分子的构建及其在清除hiv-1感染细胞中的应用
AU2019302603A1 (en) 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
JP7641223B2 (ja) * 2019-01-28 2025-03-06 サイフォス、バイオサイエンシズ、インコーポレイテッド Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN110358793A (zh) * 2019-05-30 2019-10-22 南京艾德免疫治疗研究院有限公司 一种用于car-t制备的慢病毒载体制备方法
EP3980453A4 (en) * 2019-06-07 2023-07-05 The Trustees of the University of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
CN110343175B (zh) * 2019-06-26 2021-02-26 深圳市再生之城生物医药技术有限公司 抑制HIV-1病毒感染的scFv序列及其应用
WO2021178571A1 (en) * 2020-03-03 2021-09-10 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
JP2025501273A (ja) * 2021-12-31 2025-01-17 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 Ｈｉｖ感染細胞を標的とするキメラ抗原受容体ｔ細胞

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
AU2752892A (en) * 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
MX9700800A (es) * 1994-08-02 1997-11-29 Gen Hospital Corp Células portadoras de receptores de señuelo cd4 y moléculas y métodos relacionados.
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
JP6482461B2 (ja) * 2012-07-13 2019-03-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 投与に関する形質導入ｔ細胞の適合性の評価方法
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3074419B1 (en) * 2013-11-25 2018-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
CN113604491A (zh) * 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
MX2018003463A (es) * 2015-09-22 2018-09-06 Univ Pennsylvania Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih).

Similar Documents

Publication Publication Date Title
JP2018527014A5 (enExample)
US12435118B2 (en) Chimeric antigen receptor and natural killer cells expressing same
JP2021000103A5 (enExample)
JP2017524367A5 (enExample)
JP2024507996A5 (enExample)
US20170281682A1 (en) Chimeric receptors and uses thereof in immune therapy
JP2019523301A5 (enExample)
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
WO2021035093A1 (en) Chimeric inhibitory receptor
JP2024527557A5 (enExample)
WO2019087151A1 (en) Cd38-directed chimeric antigen receptor constructs
JP2022530773A5 (enExample)
WO2024086190A9 (en) Novel cd19 binders, car-t constructs comprising the same, and methods of using the same
CN115279792A (zh) 对bcma特异的抗体及嵌合抗原受体
JP2024534847A5 (enExample)
JP2022538425A5 (enExample)
JP2023518930A5 (enExample)
KR20210111244A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
JP2020500903A5 (enExample)
US20240131068A1 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
IL266950B2 (en) ?? ? cells that express chimeric antigen receptor for use in immunotherapy
US20240384293A1 (en) Viral vector production system
JP2025501273A (ja) Ｈｉｖ感染細胞を標的とするキメラ抗原受容体ｔ細胞
IL303060A (en) Chimeric receptors and methods of their use